Drugs / Advax-SM adjuvant
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05005559 Background | Aug 2021 → Mar 2022 | COVID-19 | Cinnagen | Completed | Met primary |
| — | NCT05285384 Background | Feb → Mar 2022 | COVID-19 | Cinnagen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Advax-SM adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05285384 ↗ |
| Route | Intramuscular | “administered with intramuscular injections in the deltoid muscle of the non-dominant arm” NCT05005559 ↗ |